Citations

Clear

3942 citation(s) found for "To, Van".

American Telemedicine Association: Telestroke Guidelines
Berg, J.S.P. van den, Chong, Brian W. , Gross, Hartmut, Nyström, Karin , Wechsler, Lawrence R. , Whitchurch, Sallie, Demaerschalk, Bart M. , Adeoye, Opeolu M , Schwamm, Lee H.

Mayo Clinic

Telemedicine and e-Health | April 6, 2017 | Volume: 23 | Issue: 5 | Pages: 376-389

10.1089/tmj.2017.0006 | PMID 28384077 Get It

A phase 3 trial of IV immunoglobulin for Alzheimer disease
Relkin, Norman R., Thomas, Ronald G., Rissman, Robert A., Brewer, James B., Rafii, Michael S., Dyck, Christopher H. van, Jack, Clifford R., Sano, Mary, Knopman, David S., Raman, Rema, Szabo, Paul, Gelmont, David M., Fritsch, Sandor, Aisen, Paul S., Study, For the Alzheimer's Disease Cooperative, Study, Alzheimer's Disease Cooperative, Ahern, Geoffrey, Yaari, Roy, Sabbagh, Marwan, Mirza, Nadeem, Bernick, Charles, Bell, Karen, Turner, R. Scott, Obisesan, Thomas, Chertkow, Howard, Zabar, Yuval, Knopman, David, Mintzer, Jacobo, Grossman, Hillel, Sadowski, Martin, Wu, Chuang-Kuo, Quinn, Joseph, Borrie, Michael, Petrie, William, Ott, Brian, Keegan, Andrew, Grossberg, George, Sabbagh, Marwan, Bari, Moammed, Cohen, Sharon, Richter, Ralph, Lerner, Alan, Mulnard, Ruth, Potkin, Steven, Rafii, Michael, Brockington, John, Hsiung, Robin, Schultz, Susan, Burns, Jeffrey, Jicha, Gregory, Burke, William, Arnold, Steven, Porsteinsson, Anton, Smith, Amanda, Schneider, Lon, Quiceno, Mary, Zamrini, Edward, Asthana, Sanjay, Burgat, FT, Duara, Ranjan, Dyck, Christopher van, Jack, Clifford R. , Hsiung, Ging‐Yuek Robin , Jicha, Gregory A. , Sadowski, Martin , van Dyck, Christopher H, Relkin, Norman R., Thomas, Ronald G., Rissman, Robert A., Brewer, James B., Rafii, Michael S., Dyck, Christopher H. van, Sano, Mary, Knopman, David S., Raman, Rema, Szabo, Paul, Gelmont, David M., Fritsch, Sandor, Aisen, Paul S., Study, For the Alzheimer's Disease Cooperative, Study, Alzheimer's Disease Cooperative, Ahern, Geoffrey, Yaari, Roy, Sabbagh, Marwan, Mirza, Nadeem, Bernick, Charles, Bell, Karen, Turner, R. Scott, Obisesan, Thomas, Chertkow, Howard, Zabar, Yuval, Knopman, David, Mintzer, Jacobo, Grossman, Hillel, Wu, Chuang-Kuo, Quinn, Joseph, Borrie, Michael, Petrie, William, Ott, Brian, Keegan, Andrew, Grossberg, George, Sabbagh, Marwan, Bari, Moammed, Cohen, Sharon, Richter, Ralph, Lerner, Alan, Mulnard, Ruth, Potkin, Steven, Rafii, Michael, Brockington, John, Schultz, Susan, Burns, Jeffrey, Burke, William, Arnold, Steven, Porsteinsson, Anton, Smith, Amanda, Schneider, Lon, Quiceno, Mary, Zamrini, Edward, Asthana, Sanjay, Burgat, FT, Duara, Ranjan, Dyck, Christopher van, Jack, Clifford R , Hsiung, Gink-Yuek , Jicha, Gregory A

Mayo Clinic

Neurology | April 6, 2017 | Volume: 88 | Issue: 18 | Pages: 1768-1775

10.1212/wnl.0000000000003904 | PMID 28381506 Get It

Meeting report of the 2016 bone marrow adiposity meeting
Eerden, Bram C. J. van der , Wijnen, André J. van , van Wijnen, Andre, van Wijnen, Andre J , van der Eerden, Bram C J

Mayo Clinic

Adipocyte | April 5, 2017 | Volume: 6 | Issue: 4 | Pages: 304-313

10.1080/21623945.2017.1313374 | PMID 28410005 Get It

Extent of diagnostic agreement among medical referrals
Such, Monica Van , Lohr, Robert H., Beckman, Thomas J. , Naessens, James M. , Van Such, Monica , Lohr, Robert, Beckman, Thomas

Mayo Clinic

Journal of Evaluation in Clinical Practice | April 5, 2017 | Volume: 23 | Issue: 4 | Pages: 870-874

10.1111/jep.12747 | PMID 28374457 Get It

AbstractRationale, aims and objectivesDiagnostic uncertainty is often encountered in a medical practice. Patients with ambiguous, uncertain, and undiagnosed problems are frequently referred for second opinions. Comparing referral diagnoses to final diagnoses provides an opportunity to determine how frequently final diagnoses vary and changes the direction of medical care.MethodsA retrospective study was done at a single academic medical center using a sample of 286 patients referred by physician assistants, nurse practitioners, and physicians from primary care practices from January 1, 2009 to December 31, 2010. Patients' referral and final diagnoses were compared and classified into 1 of 3 categories: referral diagnosis and final diagnosis the same, referral diagnosis better defined/refined, and referral diagnosis distinctly different from final diagnosis. Episode costs for the respective categories were calculated for the referral visit and services that occurred at our facility within the first 30 days.ResultsIn 12% (36/286) of cases, referral diagnoses were the same as final diagnoses. Final diagnoses were better defined/refined in 66% (188/286) of cases; but in 21% of cases (62/286), final diagnoses were distinctly different than referral diagnoses. Total costs for cases in category 3 (different final diagnoses) were significantly higher than costs for cases in category 1 (P = .0001) and category 2 (P = <.0001).ConclusionReferrals to advanced specialty care for undifferentiated problems are an essential component of patient care. Without adequate resources to handle undifferentiated diagnoses, a potential unintended consequence is misdiagnoses resulting in treatment delays and complications leading to more costly treatments.
Intranuclear Actin Structure Modulates Mesenchymal Stem Cell Differentiation
Sen, Buer , Uzer, Gunes , Samsonraj, Rebekah M. , McGrath, Cody , Styner, Maya , Dudakovic, Amel , Wijnen, André J. van , Rubin, Janet , van Wijnen, Andre J, Xie, Zhihui , van Wijnen, Andre J , Styner, Maya , Sen, Buer

Mayo Clinic

Stem Cells | April 5, 2017 | Volume: 35 | Issue: 6 | Pages: 1624-1635

10.1002/stem.2617 | PMID 28371128 Get It

Abstract Actin structure contributes to physiologic events within the nucleus to control mesenchymal stromal cell (MSC) differentiation. Continuous cytochalasin D (Cyto D) disruption of the MSC actin cytoskeleton leads to osteogenic or adipogenic differentiation, both requiring mass transfer of actin into the nucleus. Cyto D remains extranuclear, thus intranuclear actin polymerization is potentiated by actin transfer: we asked whether actin structure affects differentiation. We show that secondary actin filament branching via the Arp2/3 complex is required for osteogenesis and that preventing actin branching stimulates adipogenesis, as shown by expression profiling of osteogenic and adipogenic biomarkers and unbiased RNA-seq analysis. Mechanistically, Cyto D activates osteoblast master regulators (e.g., Runx2, Sp7, Dlx5) and novel coregulated genes (e.g., Atoh8, Nr4a3, Slfn5). Formin-induced primary actin filament formation is critical for Arp2/3 complex recruitment: osteogenesis is prevented by silencing of the formin mDia1, but not its paralog mDia2. Furthermore, while inhibition of actin, branching is a potent adipogenic stimulus, silencing of either mDia1 or mDia2 blocks adipogenic gene expression. We propose that mDia1, which localizes in the cytoplasm of multipotential MSCs and traffics into the nucleus after cytoskeletal disruption, joins intranuclear mDia2 to facilitate primary filament formation before mediating subsequent branching via Arp2/3 complex recruitment. The resulting intranuclear branched actin network specifies osteogenic differentiation, while actin polymerization in the absence of Arp2/3 complex-mediated secondary branching causes adipogenic differentiation.
Methylation of the mitotic checkpoint genes BUB3 and BUBR1 in lung cancer
Alzein, N. J., Deursen, Jan van, Molina, Julian R.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 9558-9558

10.1200/jco.2004.22.90140.9558 Get It

Management of Recurrent and Metastatic HPV‐Positive Oropharyngeal Squamous Cell Carcinoma after Transoral Robotic Surgery
Sims, John R. , Abel, Kathryn M. Van , Martin, Eliot J., Lohse, Christine M. , Olsen, Kerry D., Moore, Eric J. , Van Abel, Kathryn, Price, Daniel L. , Van Abel, Kathryn M

Mayo Clinic

Otolaryngology–Head and Neck Surgery | April 4, 2017 | Volume: 157 | Issue: 1 | Pages: 69-76

10.1177/0194599817696304 | PMID 28374634 Get It

ObjectiveTo describe management and oncologic outcomes for patients who develop locoregional recurrence (LRR) or distant metastasis (DM) following transoral robotic surgery for human papilloma virus (HPV)–positive oropharyngeal squamous cell carcinoma (OPSCC).Study DesignCase series with chart review.SettingTertiary care referral center.Subjects and MethodsA total of 286 patients with HPV‐positive OPSCC who underwent transoral robotic surgery–based treatment from May 2007 to May 2015.ResultsOf 286 patients (12.2%), 35 met inclusion criteria. Of these, 19 experienced an LRR and 16 developed a DM; 2 patients with LRR subsequently developed DM. In those patients with an LRR, 79% had T1/T2 tumors, and 47% had N0/N1 nodal disease, compared with 75% and 6% in the DM group, respectively. The median time to LRR or DM was 0.6 years (interquartile range [IQR], 0.4‐1.0) and 1.8 years (IQR, 1.0‐2.1), respectively. Salvage treatment with intent to cure was attempted in 23 patients (16 LRR, 7 DM). The median time from LRR or DM to last follow‐up for the 18 patients who were still alive after salvage was 1.9 years (IQR, 0.4‐3.8; range, 7 days–6.2 years). Estimated cancer‐specific survival rates at 3 years following intent‐to‐cure treatment were 63% (95% CI, 39‐100; number still at risk, 5) in the LRR group and 100% (95% CI, 100‐100; number still at risk, 2) in the DM group.ConclusionOverall, LRR and DM for HPV‐positive OPSCC following transoral robotic surgery–based therapy are infrequent. In our subset of patients who underwent intent‐to‐cure treatment, cancer‐specific survival rates were favorable. Therefore, aggressive salvage treatment for LRR and DM for HPV‐positive OPSCC should be recommended for appropriate candidates.
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1 - or BRCA2 -Associated Metastatic Breast Cancer: Ca
Somlo, George, Frankel, Paul , Cynthia, X. , García, Agustin A. , Cigler, Tessa, Cream, Leah, Harvey, Harold A., Sparano, Joseph A. , Nanda, Rita , Chew, Helen K. , Moynihan, Timothy J. , Hurria, Arti , Mortimer, Joanne , Sand, Sharon , Herzog, Josef , Tongeren, Lily R. Van, Ferry‐Galow, Katherine V., Chen, Alice P. , Ruel, Christopher , Newman, Edward M. , Gandara, David R. , Weitzel, Jeffrey N. , Arun, Banu , Vahdat, Linda T. , Goetz, Matthew P. , Beumer, Jan Hendrik , Piekarz, Richard , Weitzel, Jeffrey N , Sparano, Joseph A , Gandara, David

Mayo Clinic

Clinical Cancer Research | March 29, 2017 | Volume: 23 | Issue: 15 | Pages: 4066-4076

10.1158/1078-0432.ccr-16-2714 | PMID 28356425 Get It

Abstract Purpose: We aimed to establish the MTD of the poly (ADP-ribose) (PAR) polymerase inhibitor, veliparib, in combination with carboplatin in germline BRCA1- and BRCA2- (BRCA)-associated metastatic breast cancer (MBC), to assess the efficacy of single-agent veliparib, and of the combination treatment after progression, and to correlate PAR levels with clinical outcome. Experimental Design: Phase I patients received carboplatin (AUC of 5–6, every 21 days), with escalating doses (50-20 mg) of oral twice-daily (BID) veliparib. In a companion phase II trial, patients received single-agent veliparib (400 mg BID), and upon progression, received the combination at MTD. Peripheral blood mononuclear cell PAR and serum veliparib levels were assessed and correlated with outcome. Results: Twenty-seven phase I trial patients were evaluable. Dose-limiting toxicities were nausea, dehydration, and thrombocytopenia [MTD: veliparib 150 mg po BID and carboplatin (AUC of 5)]. Response rate (RR) was 56%; 3 patients remain in complete response (CR) beyond 3 years. Progression-free survival (PFS) and overall survival (OS) were 8.7 and 18.8 months. The PFS and OS were 5.2 and 14.5 months in the 44 patients in the phase II trial, with a 14% RR in BRCA1 (n = 22) and 36% in BRCA2 (n = 22). One of 30 patients responded to the combination therapy after progression on veliparib. Higher baseline PAR was associated with clinical benefit. Conclusions: Safety and efficacy are encouraging with veliparib alone and in combination with carboplatin in BRCA-associated MBC. Lasting CRs were observed when the combination was administered first in the phase I trial. Further investigation of PAR level association with clinical outcomes is warranted. Clin Cancer Res; 23(15); 4066–76. ©2017 AACR.
Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72 -associated amyotrophic lateral sclerosis
Chew, Jeannie , Stankowski, Jeannette N. , Hayes, Lindsey R. , Zhang, Yong‐Jie , Prudencio, Mercedes , Carlomagno, Yari , Daughrity, Lillian M. , Jansen‐West, Karen , Perkerson, Emilie A., O’Raw, Aliesha D. , Cook, Casey , Pregent, Luc , Belzil, Véronique , Blitterswijk, Marka van , Tabassian, Lilia J., Lee, Chris W. , Yue, Mei, Tong, Jimei, Song, Yuping , Castanedes‐Casey, Monica , Rousseau, Linda , Phillips, Virginia , Rademakers, Rosa , Fryer, John Denis , Rush, Beth , Pedraza, Otto , Caputo, Ana M., Desaro, Pamela , Palmucci, Carla, Robertson, A. , Diehl, Nancy N. , Wiggs, Edythe, Tierney, Michael , Braun, Laura, Farren, Jennifer, Lacomis, David , Fournier, Christina , McCluskey, Leo, Elman, Lauren , Toledo, Jon B. , McBride, Jennifer D. , Tiloca, Cinzia , Morelli, Claudia , Poletti, Barbara , Solca, Federica , Wuu, Joanne , Jockel‐Balsarotti, Jennifer , Rigo, Frank , Ambrose, Christine, Yang, Weixing , Raitcheva, Denitza , Antognetti, Giovanna, McCampbell, Alexander , Boxer, Adam L. , Brown, Robert H. , Bowser, Robert , Miller, Timothy M. , Trojanowski, John Q. , Hu, William T. , Ratti, Antonia , Benatar, Michael , Glass, Jonathan D. , Floeter, Mary Kay, Petrucelli, Leonard , Gendron, Tania F. , Zhang, Yong-Jie , Prudencio, Mercedes , Carlomagno, Yari , Jansen-West, Karen, O'Raw, Aliesha , Pregent, Luc , Belzil, Veronique , van Blitterswijk, Marka , Castanedes-Casey, Monica , Rousseau, Linda , Phillips, Virginia , Rademakers, Rosa , Fryer, John D., Desaro, Pamela , Palmucci, Carla , Robertson, Amelia , Lacomis, David , Ladha, Shafeeq , Tiloca, Cinzia , Poletti, Barbara , Solca, Federica , Prelle, Alessandro , Jockel-Balsarotti, Jennifer , Yang, Weixing , Raitcheva, Denitza , Benatar, Michael , Silani, Vincenzo , Boylan, Kevin B, Petrucelli, Leonard , Dickson, Dennis W. , Heckman, Michael G. , Ladha, Shafeeq , Datta, Abhishek , Swieten, John C. van , Miller, Bruce L. , Grossman, Murray , Berry, James D. , Traynor, Bryan J. , Disney, Matthew D. , Silani, Vincenzo , Rothstein, Jeffrey D. , Boylan, Khrista , Hu, William T.

Mayo Clinic

Science Translational Medicine | March 29, 2017 | Volume: 9 | Issue: 383 | Pages: No page available

10.1126/scitranslmed.aai7866 | PMID 28356511 Get It

Poly(GP) proteins are a promising pharmacodynamic marker for developing and testing therapeutics for treating C9ORF72 -associated amyotrophic lateral sclerosis.